| Name | Title | Contact Details |
|---|---|---|
Kathi Rinesmith |
Senior Vice President of Regulatory Affairs | Profile |
Roundtrip is the leading digital transportation marketplace for better health outcomes. We provide a simple, comprehensive patient ride ordering software that makes available a community of ride providers who complete the transport. The company is leading the industry in reducing patient no-shows through improved ride management. Roundtrip is built for healthcare professionals — care coordinators, social workers, nurses and other transport requestors —and offers easy-to-use online and mobile platforms that connect patients with non-emergency medical transportation (NEMT). Roundtrip is a comprehensive solution which supports all levels of transport: medical cars, wheelchair vans, stretcher vehicles, ALS/BLS, all payors, and all trips delivered when and where they are needed. Roundtrip is doing more than expanding access to care; we are changing how people manage their health in their everyday lives. As we address social determinants of health and aging in place, Roundtrip is driven to deliver engaged and empowered transportation experiences for our riders.
Frantz Medical Group is a Mentor, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Upsher-Smith Laboratories, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Maple Grove, MN. To find more information about Upsher-Smith Laboratories, Inc., please visit www.upsher-smith.com
Nashville Anesthesia Service is a Madison, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.